It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The interferon signalling system elicits a robust cytokine response against a wide range of environmental pathogenic and internal pathological signals, leading to induction of a subset of interferon-induced proteins. We applied DSS (disuccinimidyl suberate) mediated cross-linking mass spectrometry (CLMS) to capture novel protein–protein interactions within the realm of interferon induced proteins. In addition to the expected interferon-induced proteins, we identified novel inter- and intra-molecular cross-linked adducts for the canonical interferon induced proteins, such as MX1, USP18, OAS3, and STAT1. We focused on orthogonal validation of a cohort of novel interferon-induced protein networks formed by the HLA-A protein (H2BFS-HLA-A-HMGA1) using co-immunoprecipitation assay, and further investigated them by molecular dynamics simulation. Conformational dynamics of the simulated protein complexes revealed several interaction sites that mirrored the interactions identified in the CLMS findings. Together, we showcase a proof-of-principle CLMS study to identify novel interferon-induced signaling complexes and anticipate broader use of CLMS to identify novel protein interaction dynamics within the tumour microenvironment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); Masaryk University, Department of Experimental Biology, Faculty of Science, Brno, Czech Republic (GRID:grid.10267.32) (ISNI:0000 0001 2194 0956)
2 University of Gdansk, International Centre for Cancer Vaccine Science, Gdansk, Poland (GRID:grid.8585.0) (ISNI:0000 0001 2370 4076)
3 University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 University of Edinburgh, School of Biological Sciences, Institute of Structural and Molecular Biology, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
5 University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988); University of Gdansk, International Centre for Cancer Vaccine Science, Gdansk, Poland (GRID:grid.8585.0) (ISNI:0000 0001 2370 4076)
6 Masaryk Memorial Cancer Institute, RECAMO, Brno, Czech Republic (GRID:grid.419466.8)